These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34356084)

  • 1. Posttranscriptional Regulation of the Human ABCG2 Multidrug Transporter Protein by Artificial Mirtrons.
    Schamberger A; Várady G; Fóthi Á; Orbán TI
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells.
    Padmanabhan R; Chen KG; Gillet JP; Handley M; Mallon BS; Hamilton RS; Park K; Varma S; Mehaffey MG; Robey PG; McKay RD; Gottesman MM
    Stem Cells; 2012 Oct; 30(10):2175-87. PubMed ID: 22887864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells.
    Apáti A; Orbán TI; Varga N; Németh A; Schamberger A; Krizsik V; Erdélyi-Belle B; Homolya L; Várady G; Padányi R; Karászi E; Kemna EW; Német K; Sarkadi B
    Biochim Biophys Acta; 2008 Dec; 1778(12):2700-9. PubMed ID: 18793608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
    Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
    PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug efflux transporter ABCG2: expression and regulation.
    Kukal S; Guin D; Rawat C; Bora S; Mishra MK; Sharma P; Paul PR; Kanojia N; Grewal GK; Kukreti S; Saso L; Kukreti R
    Cell Mol Life Sci; 2021 Nov; 78(21-22):6887-6939. PubMed ID: 34586444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.
    To KK; Robey RW; Knutsen T; Zhan Z; Ried T; Bates SE
    Mol Cancer Ther; 2009 Oct; 8(10):2959-68. PubMed ID: 19825807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells.
    Saberiyan M; Ghasemi Z; Yaghoobi H
    Cancer Rep (Hoboken); 2023 Jun; 6(6):e1816. PubMed ID: 37166017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-328 acts as an anti-oncogene by targeting ABCG2 in gastric carcinoma.
    Yan BL; Li XL; An JY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6148-6159. PubMed ID: 31364115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
    Singh A; Wu H; Zhang P; Happel C; Ma J; Biswal S
    Mol Cancer Ther; 2010 Aug; 9(8):2365-76. PubMed ID: 20682644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
    Mózner O; Bartos Z; Zámbó B; Homolya L; Hegedűs T; Sarkadi B
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of ABCG2 inhibits cancer cell proliferation.
    Chen Z; Liu F; Ren Q; Zhao Q; Ren H; Lu S; Zhang L; Han Z
    Int J Cancer; 2010 Feb; 126(4):841-51. PubMed ID: 19642144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.